TW200402289A - Methods of treating gastrointestinary and genitourinary pain disorders - Google Patents
Methods of treating gastrointestinary and genitourinary pain disorders Download PDFInfo
- Publication number
- TW200402289A TW200402289A TW092113062A TW92113062A TW200402289A TW 200402289 A TW200402289 A TW 200402289A TW 092113062 A TW092113062 A TW 092113062A TW 92113062 A TW92113062 A TW 92113062A TW 200402289 A TW200402289 A TW 200402289A
- Authority
- TW
- Taiwan
- Prior art keywords
- item
- patent application
- scope
- alkyl
- functional gastrointestinal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- 208000027520 Somatoform disease Diseases 0.000 title 1
- 208000027753 pain disease Diseases 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- -1 or taken together Chemical group 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 230000000172 allergic effect Effects 0.000 claims description 12
- 208000010668 atopic eczema Diseases 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 201000006549 dyspepsia Diseases 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
- 206010008479 Chest Pain Diseases 0.000 claims description 3
- 208000025609 Urogenital disease Diseases 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 210000004514 sphincter of oddi Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract description 5
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229940117803 phenethylamine Drugs 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930186949 TCA Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960005426 doxepin Drugs 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010051394 Allergic cystitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RRXSYZFVDIRTFB-UHFFFAOYSA-N C[CH]C1=CC=C(OC)C=C1 Chemical group C[CH]C1=CC=C(OC)C=C1 RRXSYZFVDIRTFB-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 206010053459 Secretion discharge Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003504 ach effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200402289 玖、發明說明: (一)發明所屬技術領域 (卜[2-(二甲胺基)· 1-(4 -甲氧苯基)乙基]環己醇),或 其製劑學上可接受的鹽類,一般最爲人們所知道的是速悅® (v e η 1 a f a X i n e ),其相似物已揭示在美國專利 4,5 3 5,1 8 6 (Husbands et al)。此類的化合物在以往中常作抗抑憂鬱 劑使用,在美國專利執照4,5 3 5,1 86中揭示速悅及相關之 相似物製造方法可供參考。 速悅和其活性代謝物對-脫甲基速悅(〇-desmethylvenlafaxine) ,已被證實可強力抑制單胺神經傳導物質攝取,具有臨床 抗憂鬱活性之機轉。因其新穎之結構,速悅具有和其他抗 憂鬱.藥物不同之作用機轉,如屬於三環系抗憂鬱藥之德斯 皮林(desipramine)、諾斯皮林(nostriptyline)、普 垂皮林(protriptyline)、乙咪皮林(imipriamine)、阿 米皮名(amitryptyline)、垂米皮林(trimiPramine)和 多慮平(doxepin)等。 速悅之作用機轉被認爲與強力抑制單胺神經傳導物質 5 -羥色胺及正腎上腺素攝取有關。在較次要的層面上,速 悅也會抑制多巴胺的再吸收,但它不具抑制單胺氧化酵素 的活性。對-脫甲基速悅爲速悅在人體內產生的主要代謝物 ,其呈現與速悅相似的藥理性質。速悅抑制正腎上腺素和5 _ 羥色胺(5 - HT )攝取之功效,凌駕於其對手三環系抗.憂鬱藥之 上一事已被預測(Stuart A. Montgomery, M.D., Clin. Psychiatry, 54:3, March 1993)。 200402289 與傳統的三環系抗憂鬱藥相反,速悅事實上在活體外 對蕈毒驗性(m u s c a r i n i c )、組織胺性(h i s t a m i n e r g i c )或腎 , 上腺素性受體不具親和性。三環系抗憂鬱藥會和此類受體 -作用使其具各式抗乙醯膽鹼、鎭靜及心血管效應之藥理活 ^ 性。 , (二)先前技術 機能性腸胃道及泌尿生殖道失調,包括過敏性的腸道 症狀、胃食道逆流症(GERD, Gastro esophageal Reflux D i s e a s e )、過敏性的食道、非潰瘍性的消化不良、非心臟 馨 病的胸痛、膽汁的排出障礙、odd i氏括約肌機能不良、有 間隙的膀胱炎(過敏性膀胱炎)、及慢性的骨盆疼痛(包括但 不限於外陰痛、攝護腺痛和肛門疼痛)。 機能性腸胃道及泌尿生殖道失調爲慢性疾病、並無特 殊結構性、生化性或感染性病因。 過敏性腸道症候群(I B S ),又被稱爲“結腸痙攣,,,一 種常見於結腸及小腸的失調,其定義爲因腸道習慣改變導 致腹痛的症狀。I BS之典型病症爲伴隨者便祕之腹瀉,雖然 鲁 某些病患依其自身的體驗已能控制其中之一或其餘的症狀 。其他1 常見腸胃道失調症狀尙含腹部膨脹,腸蠕動引 起的疼痛、頻糞引起的疼痛、脫糞引起的疼痛、排出黏液 及因不完全的排泄而引起的不快。 非潰瘍性的消化不良爲一種胃及十二指腸機能性失調 ’其特徵爲伴有與腹瀉或便秘無關在上腹部之持續不斷或 週期性的不適、疼痛之感覺。不適爲一種負面的感覺、其 200402289 特徵爲含如易飽,餐後的飽足感或膨脹感等一種或多種的 症狀。 由非心臟病的胸絞痛病患之豐富經驗再現其發病時之 疼痛’乃因食道膨脹鼓起之容積比需要使無症狀的人引起 疼痛的小。內臟過敏症或許有助於詮釋病人的疼痛。 膽汁排出障礙的病人會覺得身體右上四分之一處或上 腹部疼痛’或可使其喪失持續數分至數小時行爲能力。此 種疼痛或許會反射至背部或肩膀病可能伴隨著噁心及暱吐 〇 有1 2%的過敏性腸道症候群患者會拜訪第一線的內科醫 生,另有25 - 50%的過敏性腸道症候群患者會拜訪胃腸專科 醫生。雖然過敏性腸道症候群被認爲是良性的,它是一種 慢性、週期性的失調,但値得注目的是患者會因接受相關 之醫學檢查、硏究、藥物治療或工作時數減少,導致直接 開支增加會對優良的生活品質帶來衝擊。 三環類抗抑鬱藥TCAs如阿米皮名、多慮平及乙咪皮林 已被證明對過敏性腸道症候群的治療是有效的。因其副作 用如鎭靜和便秘及用藥安全上的考量。因其副作用如鎭靜 和便秘及用藥安全上的考量,TCAs的使用是受限的。也有 用SSRI來治療IBS的報導。但對健康者或IBS患者而言, SSRI並無法改變藥物停留在整個腸道的時間,不像TCAs, 如乙咪皮林可延長藥物在肓腸內的停留。 (三)發明內容 本發明係對於哺乳動物,尤其是人類的機能性胃腸疾 200402289 病’如過敏性腸道症候群、慢性腹痛、非潰瘍性的消化不 良及合倂症,提供治療、預防及控制病情方法。 (四)實施方式 本發明之方法含對哺乳動物投與有效劑量之經一或數 種官能基取代苯乙胺化合物。本發明化合物含之方法具下 列結構:
A表結構式之一^部分 or4 k(CH2), 其中點線代表選擇性不飽和鍵; R1是氫原子或C1-6烷基; Φ R2是烷基; R4是氫原子、C1-6烷基、甲醯基或C2-7烷醇; R5和R6分別是獨立的氫原子、羥基、c 1 - 6烷基、C 1 - 6 烷氧基、C2-7烷醇氧基、氰基、硝基、C1-6烷锍 基、胺基、C 1 - 6烷胺基、二烷胺基其每一烷基爲 C卜6、C2-7烷醯胺基 '鹵素、三氟甲基或融合在 一起的二氧甲烯基; 200402289 R7是氯原子或C1-6院基;而η是指0,1,2,3或4 ;或一製劑學上可接受的鹽類。 應用在本發明方法時,以具有下列結構式之化合物爲
A的定義如前所述; R1是氯原子或C1-3院基; R2 是C1 - 3烷基; R5是氫原子、羥基、C1 - 3烷氧基、氯基、溴基、三 氟甲基或C 1 - 3烷基; R6是C1-3院基、C1-3院氧基、經基、氯基、漠基、 三氟甲基或C1-3烷醇氧基; R7是氫原子或C1 -3烷基; :或一製劑學上可接受的鹽類。 本發明中具最佳療效之化合物爲R5和R6兩者皆位於 間位(meta position)或者 R5或R6其一位在對位(para position)且.η 爲 2〇 値得注目的是1 -〔( 2 -二甲胺基)-1 - ( 4 -甲氧苯基) 乙基〕環己醇和1 -〔( 2 -二甲胺基)-1 - ( 4 -羥苯基)乙基 〕環己醇和其映像立體異構物及和製劑學上可接受的鹽類 -10- 200402289 當R4是甲醯基或爲C2-7的烷氧基時,如同其他具自 .· 由經基相關衍生物一樣不具效力。在以醯氧基衍生物作長 — 期治療時’其在體內經胃酸水解或經酵素分解後成爲具有 活性的前藥。 - 本發明之鹼性化合物其製劑學上可接受的鹽類,係指 自由的鹼基與等量之酸形成不具毒性鹽類之反應。可使用 無機酸或有機酸,包括鹽酸、氫溴酸、甲酸、蘋果酸、號 珀酸、硫酸、磷酸、酒石酸、醋酸、檸檬酸、草酸及其他 · 類似的酸類。非經腸製劑以用水溶性鹽類是較佳,雖以符 合製劑學上可接受鹽類的自由鹼基之本發明抗憂鬱劑作於 口服或非經腸給藥也是可以接受的。;5或R 6之鹵素取代基 可爲含氯、溴、碘或氟之取代基。 含本發明化合物之醫藥組成物可依本發明之投與方式 給藥。該活性組成物可加在任何常用的口服製劑中,包括 錠劑、膠囊和加入著色劑、香料、穩定劑及矯味劑之液體 製劑如酊劑、懸浮劑。爲調製成口服劑型,可將主成分與 修 製劑上常用製成錠劑的物質’如澱粉、碳酸鈣、乳糖、蔗 糖和磷酸鈣混合以便於製造錠劑或膠囊。若有需要時,可 添加硬脂酸錶作潤滑齊ij。 主成分也可溶於若懸浮於製劑上可接受之無菌液態載 體中,如無囷水或無菌有機溶劑或二者的混合物中。較佳 的液態載體爲適於非經腸注射所用者。主成分在以生理食 鹽水爲載體時,具有高溶解度故可溶於任何有機溶劑中, -11- 200402289 如乙二醇水溶液或聚乙烯乙二醇溶液。乙二醇水溶液中適 合之乙二醇的重量濃度以在10-75%。在其他的例子中,可 將微細的主成分分散在澱粉水溶液或羧酸甲基纖維素鈉鹽 的溶液或適宜的油劑如花生油中。當液體製劑組成物是無 菌的液體或懸浮液時,可爲肌肉內、腹膜內或皮下注射之 用。 該醫藥組成物以單一劑型較佳,例如錠劑或膠囊。在 此種劑型中以將組成物分裝成含適當劑量組成份之單一包 裝;含該組成物單一劑型包裝如包裝好之粉劑、小瓶或安 瓶。此單一劑型藥物也可爲腠囊、扁囊或錠劑或含適當數 目之上述劑型。醫藥組成物單一劑型中主成份劑量依其需 要及主成分活性而定可從2mg調整到50 mg或更多。速悅 對人類的一般每日口服劑量建議在介於75到約200 mg之 間’分2 - 3次服用,以和食物倂服較佳。人類的每日最大 口服劑量爲3 7 5 m g ’需了解的是在特殊情況下可由對此非 常專精者來決定本發明劑量。 對此非常專精者也需了解本發明投與途徑之重要性。 除常見之口服給藥外,可持續釋出劑型也是受歡迎的。其 他可接受但不受限於此的投與方式包括靜脈內、肌肉內和 腹膜內注射,皮下注射、皮下植入;可在臉頰、舌下、經 皮、直腸、陰道和鼻內給藥之給藥方法。也可使用生物腐 蝕性(b i 〇 e r 〇 d i b 1 e )、非生物腐蝕性、生物分解性( b i o d e g r a d a b 1 e )及非生物分解性給藥系統。 也需了解的是本發明乃涵蓋針對哺乳動物,尤其是人 200402289 類之過敏性腸道症候群症狀所有的治療理由及方法。本發 明的目的是對哺乳動物投與本發明組成物以治療過敏性腸 道症候群包括所有的預防性、治療性、進而抑制、矯正、 維護、治癒、或其它的治療、養生之道或投與速悅所收預 期之效。 (五)圖式簡單說明:無
-13-
Claims (1)
- 200402289 拾、申請專利範圍: 1 . 一種治療哺乳動物機能性胃腸道及泌尿生殖道疾病的治 療方法,其係對哺乳動物投與具下列結構式化合物之有 效劑量:Α表結構式之一部分 (CH2)n 其中點線代表選擇性不飽和鍵; R1是氫原子或C1-6院基; R2 是C1 - 6烷基; R4是氫原子、C1-6烷基、甲醯基或C2-7烷醇基; R5和R6分別是獨立的氫原子、羥基、C1-6烷基、C1-6 烷氧基、C2-7烷醇氧基、氰基、硝基、C1-6烷锍 基、胺基、C 1 - 6烷胺基、二烷胺基其每一烷基爲 Cl-6、C2-7烷醯胺基、鹵素、三氟甲基或融合在 一起的二氧甲烯基; R7是氫原子或Cl_6烷基;而η是指0,1,2,3或4 ;或一製劑學上可接受的鹽類。 -14- 200402289 2 .如申請專利範圍第1項之方法,其中化合物爲 Λ SAA表結構式之一部分 OR4k(CH2), 其中點線代表選擇性不飽和鍵; R1是氫原子或C1-3院基; R2 是C1-3院基; R5是氫原子、羥基、C1-3烷氧基、氯基、溴基、三氟 甲基或C 1 - 3烷基; R6是C1-3烷基、C1-3烷氧基、羥基、氯基、溴基、 三氟甲基或C 1 - 3烷醇氧基; R7是氫原子或C1 -3烷基; ;或一製劑學上可接受的鹽類。 3 .如申請專利範圍第2項之方法,其中R5和R6兩者皆位 於間位(meta position)或者 R5或R6其一在對位(para position),且 η 爲 2〇 4 .如申請專利範圍第2項之方法,其中該化合物爲1 -〔( 2 - -15- 200402289 二甲胺基)-1-(4 -甲氧苯基)乙基〕環己醇或其製劑學 上可接受的鹽類。 5 ·如申請專利範圍第2項之方法,其中該化合物爲卜〔(2 _ 二甲胺基)-1-(4 -羥苯基)乙基〕環己醇或其製劑學上 可接受的鹽類。 6 ·如申請專利範圍第1項之方法,其中所含每日有效劑量 在3 5到約7 5 m g之間。 7 ·如申請專利範圍第1項之方法,其中所含每日有效劑量 在50到約3 7 5 mg之間。 8 ·如申請專利範圍第1項之方法,其中所含每日有效劑量 在75到約200 mg之間。 9 ·如申請專利範圍第1項之方法,其中受試者爲人類。 1 〇 ·如申請專利範圍第1項之方法,其中機能性胃腸失調爲 過敏性腸道症候群(IBS )。 1 1 ·如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 有症候的 GERD (Gastro esophageal Reflux Disease 胃 食道逆流疾病)。 1 2 ·如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 過敏性食道。 1 3 .如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 非潰瘍性消化不良。 1 4 ·如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 非心臟病的胸痛。 1 5 .如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 -16- 200402289 膽汁排出障礙。 1 6 .如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 歐笛(ODDI )氏括約肌機能不良。 1 7 .如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 慢性的骨盆疼痛。 1 8 .如申請專利範圍第1項之方法,其中機能性胃腸疾病爲 間隙性膀胱炎。-17- 200402289 柒、指定代表圖: (一) 本案指定代表圖為:第( )圖。 (二) 本代表圖之元件代表符號簡單說明:捌、本案若有化學式時,請揭示最能顯示發明特徵的化學式: Ri N R2
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38130502P | 2002-05-17 | 2002-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200402289A true TW200402289A (en) | 2004-02-16 |
Family
ID=29550101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092113062A TW200402289A (en) | 2002-05-17 | 2003-05-14 | Methods of treating gastrointestinary and genitourinary pain disorders |
Country Status (21)
Country | Link |
---|---|
US (1) | US20040019101A1 (zh) |
EP (1) | EP1505960A1 (zh) |
JP (1) | JP2005530779A (zh) |
KR (1) | KR20050003464A (zh) |
CN (1) | CN1652758A (zh) |
AR (1) | AR040033A1 (zh) |
AU (1) | AU2003232137A1 (zh) |
BR (1) | BR0310083A (zh) |
CA (1) | CA2485736A1 (zh) |
CR (1) | CR7568A (zh) |
EC (1) | ECSP045436A (zh) |
IL (1) | IL165216A0 (zh) |
MX (1) | MXPA04011329A (zh) |
NO (1) | NO20044868L (zh) |
NZ (1) | NZ548950A (zh) |
RU (1) | RU2004136999A (zh) |
SG (1) | SG165991A1 (zh) |
TW (1) | TW200402289A (zh) |
UA (1) | UA81413C2 (zh) |
WO (1) | WO2003097029A1 (zh) |
ZA (1) | ZA200410157B (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7531543B2 (en) * | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
US7365076B2 (en) * | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7491723B2 (en) * | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US7550485B2 (en) * | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
US7402698B2 (en) * | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
US7419980B2 (en) * | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7524846B2 (en) * | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
US20070142367A1 (en) * | 2003-11-10 | 2007-06-21 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20050113365A1 (en) * | 2003-11-10 | 2005-05-26 | Sir Isaac Newton Enterprises Llc | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
US20060148782A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both |
US20060148783A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20060148781A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder in a non-human mammal |
US7820690B2 (en) * | 2004-03-19 | 2010-10-26 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist |
US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) * | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
GB201007032D0 (en) * | 2010-04-27 | 2010-06-09 | Dormer Tools Ltd | Twist drill for advanced materials |
CN102095461B (zh) * | 2011-01-18 | 2012-07-18 | 姚贤卿 | 复合型干度质量流量仪及干度标定测量方法 |
RU2740750C1 (ru) * | 2020-03-27 | 2021-01-20 | Аллан Герович Бениашвили | Средство для лечения функциональных заболеваний желудочно-кишечного тракта |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
EP0977558B1 (en) * | 1996-02-15 | 2003-10-01 | Janssen Pharmaceutica N.V. | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors |
US6579899B1 (en) * | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
US6121259A (en) * | 1998-11-23 | 2000-09-19 | Sepracor Inc. | Olanzapine-N-oxide compositions and methods |
ATE286398T1 (de) * | 1998-11-23 | 2005-01-15 | Sepracor Inc | Desmethylolanzapine enthaltende zusammensetzungen und verfahren |
JP2002530339A (ja) * | 1998-11-23 | 2002-09-17 | セプラコール, インク. | 2−ヒドロキシメチルオランザピン組成物及び方法 |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
WO2003090743A1 (en) * | 2002-04-24 | 2003-11-06 | Cypress Bioscience, Inc. | Prevention and treatment of functional somatic disorders, including stress-related disorders |
MXPA04012347A (es) * | 2002-06-10 | 2005-02-25 | Wyeth Corp | Nueva sal formiato de o-desmetilvenlafaxina. |
-
2003
- 2003-05-14 TW TW092113062A patent/TW200402289A/zh unknown
- 2003-05-15 CA CA002485736A patent/CA2485736A1/en not_active Abandoned
- 2003-05-15 CN CNA038112612A patent/CN1652758A/zh active Pending
- 2003-05-15 JP JP2004505028A patent/JP2005530779A/ja active Pending
- 2003-05-15 UA UA20041210379A patent/UA81413C2/xx unknown
- 2003-05-15 IL IL16521603A patent/IL165216A0/xx unknown
- 2003-05-15 US US10/438,572 patent/US20040019101A1/en not_active Abandoned
- 2003-05-15 AU AU2003232137A patent/AU2003232137A1/en not_active Withdrawn
- 2003-05-15 KR KR10-2004-7018585A patent/KR20050003464A/ko not_active IP Right Cessation
- 2003-05-15 WO PCT/US2003/015230 patent/WO2003097029A1/en active Application Filing
- 2003-05-15 EP EP03753036A patent/EP1505960A1/en not_active Withdrawn
- 2003-05-15 SG SG200607202-9A patent/SG165991A1/en unknown
- 2003-05-15 BR BR0310083-9A patent/BR0310083A/pt not_active IP Right Cessation
- 2003-05-15 MX MXPA04011329A patent/MXPA04011329A/es unknown
- 2003-05-15 NZ NZ548950A patent/NZ548950A/en unknown
- 2003-05-15 RU RU2004136999/14A patent/RU2004136999A/ru unknown
- 2003-05-16 AR ARP030101715A patent/AR040033A1/es unknown
-
2004
- 2004-11-04 CR CR7568A patent/CR7568A/es not_active Application Discontinuation
- 2004-11-09 NO NO20044868A patent/NO20044868L/no not_active Application Discontinuation
- 2004-11-17 EC EC2004005436A patent/ECSP045436A/es unknown
- 2004-12-15 ZA ZA200410157A patent/ZA200410157B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005530779A (ja) | 2005-10-13 |
CN1652758A (zh) | 2005-08-10 |
EP1505960A1 (en) | 2005-02-16 |
NO20044868L (no) | 2004-12-08 |
WO2003097029A1 (en) | 2003-11-27 |
SG165991A1 (en) | 2010-11-29 |
ECSP045436A (es) | 2005-01-03 |
CA2485736A1 (en) | 2003-11-27 |
AR040033A1 (es) | 2005-03-09 |
IL165216A0 (en) | 2005-12-18 |
MXPA04011329A (es) | 2005-02-14 |
US20040019101A1 (en) | 2004-01-29 |
BR0310083A (pt) | 2005-02-15 |
AU2003232137A1 (en) | 2003-12-02 |
ZA200410157B (en) | 2006-05-31 |
CR7568A (es) | 2005-02-08 |
NZ548950A (en) | 2008-01-31 |
RU2004136999A (ru) | 2006-06-10 |
KR20050003464A (ko) | 2005-01-10 |
UA81413C2 (en) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200402289A (en) | Methods of treating gastrointestinary and genitourinary pain disorders | |
US20230113351A1 (en) | Compositions and methods for managing disorders | |
US20090239881A1 (en) | Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments | |
PT1153603E (pt) | Novos tratamentos utilizando derivados de fenetilamina | |
WO2006023702A2 (en) | Method for treating sleep related breathing disorders with setiptiline | |
BRPI0615432A2 (pt) | composição farmacêutica, e, uso de compostos | |
JPS61277620A (ja) | 排尿困難治療剤 | |
KR20190016478A (ko) | Lsd1 억제제를 이용한 다발성 경화증의 치료방법 | |
CN1907974B (zh) | 具有镇痛作用的石杉碱甲及其衍生物 | |
KR20090110889A (ko) | 우울증 치료용 카바메이트 화합물 | |
KR20090036114A (ko) | 무스카린성 수용체 m1 길항제를 이용한 심리 질환 치료 방법 | |
JP2004521150A (ja) | 尿失禁治療用アリール(またはヘテロアリール)アゾリルカルビノール誘導体 | |
CN104487427B (zh) | 四唑衍生物和它们作为钾通道调节剂的用途 | |
WO2003097031A1 (fr) | Medicament contre l'obesite a base de methylidene hydrazide | |
TWI296522B (en) | Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients | |
JP6067022B2 (ja) | 情動障害の予防又は治療に用いるためのn−置換ベンゼンプロパンアミド又はベンゼンプロペンアミド | |
WO2004026296A1 (ja) | 抗ストレス性疾患組成物 | |
JP4552189B2 (ja) | 脊柱管狭窄症治療剤 | |
JP2004508272A (ja) | アセチルコリンエンハンサー | |
US20050222263A1 (en) | Compositions against stress-related diseases and methods for treating stress-related diseases | |
JPH0393719A (ja) | セルトラリンからなる薬物依存症治療剤 | |
BRPI0609276A2 (pt) | benzoxazocinas e seu uso terapêutico | |
US20080176951A1 (en) | Methods of treating gastrointestinary and genitourinary pain disorders | |
US9265774B2 (en) | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
US20050065218A1 (en) | Utilization of alverine, alone or in combination with tricyclic antidepressant or a specific serotonin reuptake inhibitor for the treatment of depression |